-
Uncategorized3 weeks agoParkinson’s drug from Biogen, Denali comes up short
High level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain...
-
Uncategorized3 weeks ago
Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout...
-
Uncategorized3 weeks agoSTAT+: EU and US advisers split over AstraZeneca breast cancer drug
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Merck’s bet on an antibody-drug...
-
Uncategorized3 weeks agoNews round-up from SLAS Europe
DDW reports on some key news releases that emerged out of this year’s SLAS Europe. Cenevo reinforces agentic AI approach with new AI-assistant Announced at SLAS Europe, lab management...
-
Uncategorized3 weeks ago
Why one health AI unicorn is giving away its service for free
Why one health AI unicorn is giving away its service for free
-
Uncategorized3 weeks ago
Recordati fields $12.4B go-private offer
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to...
-
Uncategorized3 weeks ago
Gilead inks $140M API supply deal, tightening ties to Korean manufacturer
The agreement is the largest in a series of deals that Gilead Sciences has penned with Korea’s Yuhan.
-
Uncategorized3 weeks ago
Biogen, Denali pull plug on Parkinson’s program after mid-stage flop
Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing both primary and secondary endpoints.
-
Uncategorized3 weeks ago
Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop
Biogen and Denali Therapeutics’ LRRK2 inhibitor has flunked a Phase 2b trial in early Parkinson’s disease, leading the companies to drop the program in certain patients....
-
Uncategorized3 weeks agoSTAT+: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion
Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, has raised more money at a $1.8 billion valuation, it announced Friday. Retro has a...
STAT+: At hospital finance conference, a call to end the friction that’s keeping costs high
Beyond sunshine: Iberia’s biotech moment has arrived with developing capital networks
